Qualifying medical marijuana is Schedule III, while adult-use remains Schedule I. That distinction could reshape the economics of every dual-license cannabis operation.
August 18, 2026
A few years ago, maintaining a medical cannabis license looked like an exercise in nostalgia.
Patient counts were falling. Medical shelves were shrinking. Adult-use had the volume, investment and momentum. For many operators, the medical license became an administrative expense attached to a market that had already moved on.
The April federal scheduling order may have turned that neglected license into one of the most valuable assets in the business.
New Jersey’s medical program peaked at 129,369 registered patients in May 2022. By mid-May 2026, it was down to 46,881, according to the state’s Cannabis Regulatory Commission.
Similar declines followed adult-use legalization elsewhere. Arizona’s registry fell roughly 70% from its peak. Michigan medical sales dropped below 1% of adult-use sales while operators continued managing separate licenses, inventory and records.
Operators followed the customer. Products built around particular conditions gave way to products built for volume and THC. Patient education budgets became consumer-marketing budgets. Some companies let their medical licenses lapse. Others kept them because losing one felt more permanent than paying another renewal fee.
Then Washington changed the calculation.
The reversal
On April 22, Acting Attorney General Todd Blanche signed an order moving two categories of marijuana from Schedule I to Schedule III: marijuana contained in FDA-approved drug products and marijuana subject to a qualifying state medical-marijuana license.
The order was published and took effect April 28. Marijuana outside those categories, including adult-use marijuana, remains Schedule I. The distinction appears in the final rule.
That dividing line matters because Section 280E applies to trafficking in Schedule I or II controlled substances. It does not apply to Schedule III.
Qualifying medical activity may therefore sit outside 280E while adult-use activity remains subject to it.
A medical license that produces only a small share of a company’s revenue could determine which portion of the business can deduct payroll, rent, marketing, technology and other operating expenses.
The benefit could be substantial. Capturing it will require more than holding the right piece of paper.
The tax benefit is not automatic
Treasury and the IRS plan to issue guidance for businesses with both medical and adult-use activity. That guidance is expected to address how shared expenses should be allocated between activities receiving different federal tax treatment.
It has not been published.
Treasury has said it expects Schedule III treatment to apply for the entire taxable year containing April 28. For a calendar-year taxpayer, that could mean January 1, 2026. Until guidance is issued, operators should treat that as the government’s intended approach rather than settled tax treatment. Treasury outlined its expectations in April.
Consider a dispensary operating both licenses from one building. Employees work across both sides. Security covers the entire property. Marketing promotes the same brand. Technology, professional services and management are shared.
The company must determine which expenses belong to qualifying medical activity, which belong to adult-use and how the remaining shared costs should be divided.
Possible approaches include separate cost centers, direct expense tracing, entity separation and SKU- or batch-level inventory tracking. None currently qualifies as a federal safe harbor.
A separation that exists only in a spreadsheet is unlikely to withstand scrutiny. The distinction should be visible in the company’s licenses, books, contracts, inventory records and daily operation.
The issue may be especially complicated for companies that built multi-entity structures years ago to manage 280E. Those structures may no longer serve the same purpose for medical activity. In some cases, they could make it harder to establish which entity performed each function and incurred each expense.
A structure designed for the previous tax environment should be reviewed before it is carried into the new one.
What operators can do now
The most useful early steps are those that strengthen the company’s records without locking it into a permanent structure.
Medical and adult-use transactions should be identifiable. Inventory tagging should follow products through the operation. Cost centers should reflect how employees, facilities and services are actually used. Any allocation methodology should be documented, applied consistently and supported by contemporaneous records.
Someone unfamiliar with the business should be able to reconstruct the company’s reasoning two years from now.
Operators should also confirm their DEA-registration status. Applying during the final rule’s initial 60-day window provided special interim and expedited treatment. Missing that window did not create permanent ineligibility, but it may affect which early-applicant provisions are available.
Permanent decisions deserve more caution until Treasury issues guidance. Deal pricing should not assume 280E relief across the entire company. Acquisitions should not value every medical license the same way. A license may be valuable only if the operation, inventory and records behind it support qualifying medical activity.
The immediate priority is building a defensible record. Any tax savings will depend on the company’s ability to support its position.
Build for more than one outcome
The medical license looked obsolete because the market moved away from it. Federal law has given it a new purpose.
Operators best positioned to benefit will have clean records, visible separation between medical and adult-use activity, and financial systems that can adapt as Treasury fills in the details.
That kind of preparation has value beyond one tax position. It gives operators a clearer view of their business, stronger documentation for financial partners and more flexibility when the rules change again.
Safe Harbor has spent more than a decade helping cannabis businesses build transparent, durable financial infrastructure. If the new medical and adult-use distinction is affecting how activity moves through your accounts, reporting and banking relationships, the time to examine those systems is before Treasury guidance arrives.
This article reflects the public record as of August 18, 2026. Nothing in this article is tax or legal advice. Operators should consult qualified counsel and tax professionals before taking a position.